I-Mab ADR (NASDAQ: IMAB) started the day on Wednesday, with a price increase of 11.97% at $1.10, before settling in for the price of $0.98 at the close. Taking a more long-term approach, IMAB posted a 52-week range of $0.84-$2.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 1181.20%. Meanwhile, its Annual Earning per share during the time was -18.89%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 87.13%. This publicly-traded company’s shares outstanding now amounts to $77.02 million, simultaneously with a float of $76.81 million. The organization now has a market capitalization sitting at $84.72 million. At the time of writing, stock’s 50-day Moving Average stood at $1.0090, while the 200-day Moving Average is $1.3815.
I-Mab ADR (IMAB) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. I-Mab ADR’s current insider ownership accounts for 0.27%, in contrast to 18.64% institutional ownership.
I-Mab ADR (IMAB) Earnings and Revenue Records
I-Mab ADR’s EPS increase for this current 12-month fiscal period is 87.13% and is forecasted to reach -0.47 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 26.00% through the next 5 years, which can be compared against the -18.89% growth it accomplished over the previous five years trading on the market.
I-Mab ADR (NASDAQ: IMAB) Trading Performance Indicators
Let’s observe the current performance indicators for I-Mab ADR (IMAB). It’s Quick Ratio in the last reported quarter now stands at 16.50. The Stock has managed to achieve an average true range (ATR) of 0.11. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 77.02.
In the same vein, IMAB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.55, a figure that is expected to reach -0.06 in the next quarter, and analysts are predicting that it will be -0.47 at the market close of one year from today.
Technical Analysis of I-Mab ADR (IMAB)
If we take a close look at the recent performances of I-Mab ADR (NASDAQ: IMAB), its last 5-days Average volume was 1.09 million that shows progress from its year to date volume of 1.09 million. During the previous 9 days, stock’s Stochastic %D was recorded 38.13% While, its Average True Range was 0.1260.
Raw Stochastic average of I-Mab ADR (IMAB) in the period of the previous 100 days is set at 32.42%, which indicates a major fall in contrast to 46.33% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 102.35% that was higher than 81.64% volatility it exhibited in the past 100-days period.
